OphthaliX Inc.
123 West Nye Lane
Suite 129
Carson City
Nevada
89706
United States
Tel: 972-3-9241114
Fax: 972-3-9249378
Website: http://www.ophthalix.com/
Email: info@ophthalix.com
13 articles about OphthaliX Inc.
-
OphthaliX Inc. Announces Phase II Glaucoma Data
7/5/2016
-
OphthaliX Inc. Announces CF101 Is Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma
12/17/2015
-
Can-Fite BioPharma Subsidiary OphthaliX Inc. Signs Definitive Agreement To Acquire Improved Vision Systems
6/19/2015
-
OphthaliX Inc. Signs Term Sheet To Acquire Improved Vision Systems Ltd.
5/4/2015
-
OphthaliX Inc. Provides An Update On Its Clinical Developments And Strategic Plans
6/9/2014
-
OphthaliX Inc.'s Dry Eye Drug CF101 Fails To Meet Goals In Phase 3 Study
12/31/2013
-
OphthaliX Inc. Release: European Patent Office Grants a Patent for the Treatment of Sjogren's Syndrome
9/4/2013
-
OphthaliX Inc. Appoints Dr. Michael Belkin to its Board of Directors
7/3/2013
-
OphthaliX Inc. Release: Third Party Presented New Data at the ARVO 2013 Annual Meeting in Seattle, WA, Validating the use of A3 Adenosine Receptor Agonists for Lowering Intra Ocular Pressure and for the Treatment of Glaucoma
5/13/2013
-
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
3/18/2013
-
Dr. Gil Ben-Menachem Appointed Chief Executive Officer of OphthaliX Inc.
12/13/2012
-
OphthaliX Inc. Reports First Quarter 2012 Financial Results
5/16/2012
-
OphthaliX Inc. Successfully Completed Preclinical Studies Showing the Efficacy of CF101 for the Treatment of Anterior Uveitis
4/10/2012